BACKGROUND: Prophylactic neck dissection (PND) for papillary thyroid cancer is controversial. The objective of this study was to analyze the influence of PND on the rate of retreatment. METHODS: In this retrospective case-control study, papillary thyroid carcinomas >10 mm without ultrasonographic evidence of nodal disease (cN0) were treated with total thyroidectomy (TT) or TT with bilateral central compartment PND. All received postoperative radioactive iodine ((131)I) and were followed for at least 1 year. We compared the rate of retreatment (surgery or (131)I). RESULTS: Altogether, 246 patients (mean age 46 years, 78 % women) underwent TT (n = 91) or TT + PND (n = 155). The groups were similar in age, sex, tumor size, and follow-up (median 6.3 years) (p > 0.05). Overall, 11 (12 %) of the patients in the TT group underwent reoperation in the central compartment for recurrence versus 3 (2 %) in the TT + PND group (p < 0.001). There were 1.18 administrations of (131)I for the TT group versus 1.08 for the TT + PND group (p = 0.08). The average cumulative dose of (131)I was 3.9 ± 1.8 GBq for the TT group and 3.8 ± 1.3 GBq for the TT + PND group (p = 0.52). Actuarial (Kaplan-Meier) 5-year retreatment rates were 14.7 % in the TT group and 6.5 % in the TT + PND group (p = 0.01, log-rank). The rate of permanent recurrent nerve paralysis was 2 % for the TT group and 1 % for the TT + PND group (p = 0.98). The rates of permanent hypoparathyroidism were 7 versus 3 %, respectively (p = 0.12). CONCLUSIONS: Five-year retreatment rates were lower in patients treated with PND, with no added permanent morbidity.
BACKGROUND: Prophylactic neck dissection (PND) for papillary thyroid cancer is controversial. The objective of this study was to analyze the influence of PND on the rate of retreatment. METHODS: In this retrospective case-control study, papillary thyroid carcinomas >10 mm without ultrasonographic evidence of nodal disease (cN0) were treated with total thyroidectomy (TT) or TT with bilateral central compartment PND. All received postoperative radioactive iodine ((131)I) and were followed for at least 1 year. We compared the rate of retreatment (surgery or (131)I). RESULTS: Altogether, 246 patients (mean age 46 years, 78 % women) underwent TT (n = 91) or TT + PND (n = 155). The groups were similar in age, sex, tumor size, and follow-up (median 6.3 years) (p > 0.05). Overall, 11 (12 %) of the patients in the TT group underwent reoperation in the central compartment for recurrence versus 3 (2 %) in the TT + PND group (p < 0.001). There were 1.18 administrations of (131)I for the TT group versus 1.08 for the TT + PND group (p = 0.08). The average cumulative dose of (131)I was 3.9 ± 1.8 GBq for the TT group and 3.8 ± 1.3 GBq for the TT + PND group (p = 0.52). Actuarial (Kaplan-Meier) 5-year retreatment rates were 14.7 % in the TT group and 6.5 % in the TT + PND group (p = 0.01, log-rank). The rate of permanent recurrent nerve paralysis was 2 % for the TT group and 1 % for the TT + PND group (p = 0.98). The rates of permanent hypoparathyroidism were 7 versus 3 %, respectively (p = 0.12). CONCLUSIONS: Five-year retreatment rates were lower in patients treated with PND, with no added permanent morbidity.
Authors: K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf Journal: Arch Otolaryngol Head Neck Surg Date: 2002-07
Authors: Aleksandra Popadich; Olga Levin; James C Lee; Stephanie Smooke-Praw; Kevin Ro; Maisam Fazel; Asit Arora; Neil S Tolley; Fausto Palazzo; Diana L Learoyd; Stan Sidhu; Leigh Delbridge; Mark Sywak; Michael W Yeh Journal: Surgery Date: 2011-12 Impact factor: 3.982
Authors: Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Carlos Suárez; Phillip K Pellitteri; Ashok R Shaha; Marc Hamoir; K Thomas Robbins; Avi Khafif; Juan P Rodrigo; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito; Dana M Hartl Journal: Eur Arch Otorhinolaryngol Date: 2014-06-11 Impact factor: 2.503
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti Journal: J Endocrinol Invest Date: 2018-05-04 Impact factor: 4.256
Authors: Panagiotis Asimakopoulos; Ashok R Shaha; Iain J Nixon; Jatin P Shah; Gregory W Randolph; Peter Angelos; Mark E Zafereo; Luiz P Kowalski; Dana M Hartl; Kerry D Olsen; Juan P Rodrigo; Vincent Vander Poorten; Antti A Mäkitie; Alvaro Sanabria; Carlos Suárez; Miquel Quer; Francisco J Civantos; K Thomas Robbins; Orlando Guntinas-Lichius; Marc Hamoir; Alessandra Rinaldo; Alfio Ferlito Journal: Curr Oncol Rep Date: 2020-11-14 Impact factor: 5.075